Trial Profile
A retrospective study to assess clinical parameters like Older Age, Malignant Pleural Effusion, and Symptomatic Metastatic Disease as predictors to poor outcome after Lenvatinib Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Apr 2018
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 23 Apr 2018 New trial record
- 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society